Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a retrospective study characteristics of 729 climacteric and postmenopausal women with hyperplasia and adenocarcinoma of the endometrium are compared with those of 82 women with atrophic endometrium and 96 women with carcinoma of the cervix. In a prospective study 225 women with glandular-cystic, adenomatous and atypical hyperplasia of the endometrium have been checked by a control-curettage within a period of two months until four years following the first diagnosis. Low parity, disturbances of menstruation with anovulatoric bleedings during fertility period, adipositas, hypertension and diabetes mellitus in climacteric and postmenopausal women indicate a high risk of carcinoma of the endometrium. Hyperplasias of the endometrium in climacteric women cannot be considered as precursors of corpus carcinoma. They are the result of a temporary hormonal dysfunction. Prophylactic hysterectomy, however, should be performed, if adenomatous or atypical hyperplasia appears in older postmenopausal women with the indicators of high risk of endometriumcarcinoma as mentioned above.
 ...
PMID:[Epidemiology of endometrial hyperplasia and adenocarcinoma]. 97 98

Dr. Boyd C. Quint recently presented important data regarding the relationship of estrogen therapy to the risk of endometrial carcinoma, but the data seem to have been inappropriately analyzed. Dr. Quint studied 291 postmenopausal women who received primary treatment for endometrial carcinoma at the Swedish Hospital Medical Center in Seattle, Washington between 1960 and 1973. The 1st step in Quint's analysis was a determination of the ratio of new endometrial carcinoma cases to the total "major gynecologic operations" for the intervals 1960-1966 and 1966-1973. This ratio was observed to increase from about 2% for 1960-1966 to about 4% for 1966-1973, but this change -- while statistically significant - cannot be used to support the hypothesis that the absolute incidence of endometrial carcinoma increased from the 1st to the 2nd interval. The 2nd step in the analysis was a determination of the incidence of nulliparity, obesity and hypertension, and/or diabetes and prior estrogen therapy among the endometrial carcinoma patients 1st treated in each of the 2 intervals. The prevalence of the constitutional stigma commonly associated with endometrial carcinoma, obesity and hypertension and/or diabetes can be seen to be significantly lower among the 203 patients 1st treated between 1966 and 1973 than among the 88 patients 1st treated between 1960 and 1966. Conversely, the prevalence of prior estrogen therapy is seen to be much higher. Data indicating that approximately 50% of Seattle area women had used or were using estrogen therapy by 1973 to 1974 - median use of about 10 years - are in press. Quint's data do support the hypothesis that estrogen therapy may be an etiologic factor among the more recent cases of endometrial carcinoma.
 ...
PMID:Estrogen therapy and endometrial carcinoma. 98 96

Diabetes and obesity were noted in 21.3% and 42.3% respectively of 94 patients with adenocarcinoma corporis uteri. Hypertension and ovarian or mammary neoplasia were also common. Obese and diabetic subjects proved more sensitive to treatment with high doses of medroxyprogesterone acetate. Screening for precancerous states or carcinoma of the endometrium in obese and diabetic women is suggested.
 ...
PMID:[Diabetes, obesity and adenocarcinoma of corpus uteri]. 99 85

An analysis is made of 3 reports of American studies which linked the postmenopausal use of estrogens to endometrial cancer. In regard to the accuracy of these studies, the author emphasizes that proper attention must be paid 1st to the state of those subjects in the control group and, more importantly, to the presence of other risk factors in the patients. Most disorders and diseases in which estrogens are employed as therapy are also noted to be risk factors in the diagnosis of endometrial carcinoma. These include adiposity, diabetes, high blood pressure, infertility, prolonged cyclical disruptions, menopause, and the social status of the patient (in which the increased use of estrogens and other possible carcinogens is noted to exceed that of poorer class patients). The possible dangers of the use of estrogens are recognized, however, and must certainly be particularly considered when the patient shows 1 or more other risk factors. A guideline for postmenopausal administration of estrogens is given.
 ...
PMID:[Estrogens and carcinoma of the endometrium]. 100 92

142 patients with endometrial cancer, and an equal size control group, were compared in regard to age, obesity, diabetes, hypertension, vaginal cytology, and endometrial histology. In a 2nd study, 335 patients with endometrial cancer were treated with abdominal hysterectomy, bilateral salpingo-oophorectomy, and radiation applications. In an experimental study, the percent of conversion of androstenedione to estrone in subcutaneous adipose tissue in 20 patients was studied using an in vitro method. The 1st clinical study showed that the frequency of diabetes, hypertension, the estrogen effect in the vaginal smear, and proliferative changes in the endometrium were significantly higher than in the control group. Obesity was also more frequent. The 2nd clinical study showed a survival rate of more than 5 years in certain parameters. The experimental in vitro study showed a higher aromatization of androstenedione to estrone in cancer patients, indicating etiological correlations between endometrial cancer and extraglandular estrone production.
 ...
PMID:Estrogens and endometrial cancer: aspects of etiology and survival rate. 102 Oct 8

The use of estrogens almost tripled during the 1965-75 period, with usage concentrated as a cure-all for aging, for the degenerative diseases associated with aging, and for the emotional difficulties of middle age. 3 separate studies published in the last year have shown a high level of association between estrogen use and the development of endometrial cancer. Results of these studies coupled with the significant recent increase in the incidence of cancer in women over 50 who are in the high socioeconomic groups--the groups most likely to use estrogen therapy--emphasize the association. The U.S. FDA has proposed a modification in the labeling for estrogens, and a package insert for patients which would warn of possible hazards of estrogen therapy. It is recommended that estrogen be used only for vasomotor symptoms and vaginal atrophy. The lowest possible effective dosage should be used and for the shortest possible amount of time. Earlier studies had suggested that estrogen replacement therapy might protect against breast cancer; most recent studies suggest the opposite. In addition, estrogen may trigger high blood pressure and increase some blood clotting. Women with high blood pressure or a family history of early heart attacks are contraindicated from using estrogen therapy. Even for the treatment of osteoporosis, there may be safer alternative therapies. Women are cautioned as to their own responsibilities when taking estrogens.
 ...
PMID:Estrogen therapy: the dangerous road to Shangri-La. 102 54

Endometrial carcinoma developed in a teenager with obesity, hypertension, hyperestrinism and lack of diurnal variation of plasma cortisol concentration. She underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy and is receiving estrogen therapy. Her six obese sisters and her mother, who are at risk for endometrial carcinoma, are being managed conservatively.
 ...
PMID:Adenocarcinoma of the endometrium in a teenager. 113 70

To determine the association between the incidence of endometrial cancer and the use of estrogen in menopausal and post-menopausal women, we retrospectively compared 317 patients with adenocarcinoma of the endometrium with an equal number of matched controls having other gynecologic neoplasms; 152 patients used estrogen, as compared to 54 of 317 controls. Thus, the risk of endometrial cancer was 4.5 times greater among women exposed to estrogen therapy. When estrogen use was adjusted for concomitant variables such as obesity, hypertension, diabetes, parity, referral pattern, age at diagnosis, year of diagnosis and other gynecologic neoplasms, the magnitude of the increased relative risk was associated with several of these variables, and was highest in patients without obesity and hypertension. Exogenous estrogen therapy is associated with an increased risk of endometrial carcinoma, but this increased relative risk is less apparent in patients with physiologic characteristics previously associated with an increased risk.
 ...
PMID:Association of exogenous estrogen and endometrial carcinoma. 118 89

In a case-control-study an epidemiological investigation of cancer of the endometrium was carried out. 407 patients with cancer of the endometrium were compared with a control group of 450 women. The patients with endometrial cancer differed from the control group in the following manner: Significantly higher incidence of diabetes mellitus and hypertension. Overweight could not be printed out reliably, but there are so many corresponding statements in literature about a higher degree of overweight that there could be no doubt about it. Furthermore the patients with carcinoma of the uterine corpus had an earlier menarche, a later menopause, a smaller number of deliveries and more menstrual abnormalities. They were more exposed to radiation in the pelvis, the incidence of malignant tumors was higher in their families. So factors of high risk related to cancer of the endometrium could be defined.
 ...
PMID:[Epidemiological aspects of corpus carcinoma]. 118 76

The withdrawal from the market of the oral contraceptives Volidan 21 and Serial 28 was based on work in beagle dogs treated for 7 years with high doses of megestrol acetate. The treated animals developed significantly more tumors than untreated controls. Chlormadinone acetate was withdrawn from clinical use in 1970 on the basis of similar reports. All other progestogens in use in Britain had no effect on the incidence of tumors. The only neoplasm linked with oral contraceptives by clinical evidence is hepatic adenoma. In menopausal and postmenopausal patients estrogen therapy may increase the risk of endometrial uterine cancer. For most young women oral contraception is a compromise between safety and reliability. Serious thromboembolic complications increase with age, cigarette smoking, and hypertension. Patients should be screened for the presence of risk factors and the effects of treatment regularly assessed. In menopausal women, regular monitoring for endometrial cancer is advised. Medical supervision of hormone therapy is needed.
 ...
PMID:Editorial: Cancer risks from hormone treatment. 120 97


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>